GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Laurus Labs Ltd (BOM:540222) » Definitions » Institutional Ownership

Laurus Labs (BOM:540222) Institutional Ownership : 36.21% (As of Dec. 15, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Laurus Labs Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Laurus Labs's institutional ownership is 36.21%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Laurus Labs's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Laurus Labs's Float Percentage Of Total Shares Outstanding is 0.00%.


Laurus Labs Institutional Ownership Historical Data

The historical data trend for Laurus Labs's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Laurus Labs Institutional Ownership Chart

Laurus Labs Historical Data

The historical data trend for Laurus Labs can be seen below:

2024-02-29 2024-03-31 2024-04-30 2024-05-31 2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30
Institutional Ownership 27.78 34.14 35.84 36.00 36.13 35.58 35.49 35.13 36.22 36.21

Laurus Labs Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Laurus Labs Business Description

Traded in Other Exchanges
Address
Road No. 7, Banjara Hills, 2nd Floor, Serene Chambers, Hyderabad, TG, IND, 500034
Laurus Labs Ltd is a pharmaceutical company based in India. It provides active pharmaceuticals ingredients (API) including intermediates, Generic Finished dosage forms (FDF) and Contract Research services. The entity develops APIs and intermediates for select, high-growth antiretrovirals, Hepatitis C and Oncology. It also manufactures APIs in other therapeutic areas, such as anti-asthma, ophthalmology, anti-diabetics, cardiovascular, proton pump inhibitors, among others. The company has its business presence in India and Outside India of which it derives a majority of revenue from Outside India. It generates revenue from the sale of API, Intermediates and Formulations, Contract research services and others.

Laurus Labs Headlines

No Headlines